Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?

AI-generated analysis

🧬 Bristol Myers Squibb (BMY) and Gilead Sciences (GILD) are both leading biotech companies with diversified portfolios, making direct comparison complex.

πŸ₯ Bristol Myers' revenue growth is driven by its immuno-oncology franchise, with Opdivo remaining the top revenue generator across oncology and cardiovascular areas.

πŸ’Š Key new products for Bristol Myers include Reblozyl, which exceeded $2 billion in annualized sales, and Cobenfy, a novel schizophrenia drug generating $155 million in 2025.

πŸ“‰ Legacy products at Bristol Myers account for about 45% of revenues and face increasing pressure from generic competition that could limit near-term growth.

🀝 Bristol Myers is pursuing an aggressive acquisition and collaboration strategy, recently partnering with BioNTech to co-develop a bispecific antibody for solid tumors.

⚠️ Despite its growth ambitions, Bristol Myers reported a high debt-to-capital ratio of 70.9% as of December 2025 due to significant deal-making costs.

🦠 Gilead maintains a dominant market position in HIV treatment with Biktarvy holding over 52% market share and strong leadership in prevention with Descovy.

πŸ“ˆ Gilead's HIV portfolio grew 6% in 2025, excluding a $900 million headwind from Medicare Part D redesign, indicating underlying strength in the segment.

πŸ’‰ The FDA approval of injectable lenacapavir (Yeztugo) strengthens Gilead's HIV pipeline by offering improved adherence through twice-yearly dosing.

πŸ“Š Management expects Gilead's total HIV sales to grow approximately 6% year over year, supported by potential new treatments like GS-3242.

🌿 Gilead has expanded its liver disease portfolio with the FDA approval of seladelpar (Livdelzi) for the treatment of primary biliary cholangitis.

πŸ’° Investors must weigh Bristol Myers' growth momentum and high leverage against Gilead's strong cash flow and dominant franchise positions in HIV.

Bullish Signals
  • Gilead Sciences delivered a 6% year-over-year growth in HIV sales for 2025, excluding a $900 million headwind, which translates to estimated 10% organic growth, demonstrating resilient demand despite market headwinds.
  • The prevention portfolio for Gilead saw an impressive 47% surge in 2025, driven by strong performance of Descovy which increased sales 31% year-over-year to $2.8 billion.
  • Descovy has secured more than 45% market share in the U.S. PrEP segment, cementing Gilead's dominant leadership position in HIV prevention.
  • The FDA approval of Yeztugo (lenacapavir) adds a first-in-class twice-yearly dosing option that offers significant adherence advantages and is projected to generate $800 million in revenues by 2026.
  • Gilead's pipeline includes GS-3242, a long-acting integrase inhibitor approved in combination with lenacapavir, ready to further strengthen its HIV franchise with twice-yearly treatment options.
  • Bristol Myers Squibb is successfully launching new products like Opdivo Qvantig and Opdualag, with the latter becoming a standard-of-care option in first-line melanoma.
  • Partnership product Reblozyl has exceeded $2 billion in annualized sales, driven by robust uptake in MDS-related anemia and benefiting from ongoing label expansions.
  • Bristol Myers' newer therapies like Breyanzi have surpassed a $1 billion run rate with significant upside expected in 2026 following strong demand and additional label expansions.
  • The launch of Cobenfy generated $155 million in revenues in 2025, representing the first novel pharmacological approach to schizophrenia in decades with potential for long-term growth through future label expansions.
Risk Factors
  • Despite a robust pipeline, Bristol Myers Squibb faces significant leverage risks with a debt-to-capital ratio of 70.9% as of Dec. 31, 2025, citing $42.8 billion in long-term debt against only $10.2 billion in cash.
  • Legacy products accounting for about 45% of Bristol Myers' revenues are under mounting pressure from generic competition, which is expected to weigh on near-term top-line growth.
  • Gilead Sciences HIV sales growth of 6% in 2025 was partially delivered despite an estimated $900 million headwind from the Medicare Part D redesign.
  • Bristol Myers Squibb has increased leverage through its aggressive deal-making strategy, which includes partnerships with BioNTech and acquisitions like Orbital Therapeutics to offset generic competition pressures.
Full Analysis
This analysis compares Bristol Myers Squibb (BMY) and Gilead Sciences (GILD), two major biopharmaceutical companies with diversified portfolios but distinct strategic strengths. Bristol Myers maintains a robust lineup spanning oncology, hematology, immunology, cardiovascular, neuroscience, and other therapeutic areas, while its growth is heavily anchored in immuno-oncology. The company's growth franchise, which includes key therapies like Opdivo, Opdivo Qvantig, Reblozyl, and Breyanzi, accounted for roughly 55% of total revenues in 2025. Opdivo remains the top revenue generator with ongoing label expansions, while newer products like Cobenfy generated $155 million in 2025 as a novel treatment for schizophrenia. However, legacy products make up about 45% of revenues and face mounting generic competition. To counter this, Bristol Myers is pursuing acquisitions and collaborations, such as the acquisition of Orbital Therapeutics and a partnership with BioNTech to co-develop pumitamig. Financially, Bristol Myers has increased its leverage significantly; as of December 31, 2025, the company reported a debt-to-capital ratio of 70.9%, holding $10.2 billion in cash against $42.8 billion in long-term debt. In contrast, Gilead Sciences is best known for its dominant position in HIV treatment and prevention, with its franchise led by Biktarvy and Descovy. HIV product sales grew 6% in 2025, driven by a 7% increase in Biktarvy and a 47% surge in the prevention portfolio, excluding a $900 million headwind from Medicare Part D redesign. Biktarvy holds more than 52% of the market share, while Descovy increased sales by 31% year-over-year to $2.8 billion, capturing over 45% of the U.S. PrEP market. The FDA approval of lenacapavir (Yeztugo), a first-in-class capsid inhibitor, is projected to generate approximately $800 million in revenues for 2026. Gilead also has a strong liver disease portfolio, strengthened by the approval of seladelpar (Livdelzi) for primary biliary cholangitis. The company expects total HIV sales, including treatment and prevention, to grow about 6% year-over-year going forward. The choice between these two stocks depends on an investor's risk tolerance regarding growth versus financial leverage. Bristol Myers is characterized by aggressive deal-making to offset legacy product erosion and fund expansion in its IO franchise, but this strategy has resulted in a high debt-to-capital ratio of 70.9%, presenting a key financial risk alongside its growth ambitions. Gilead offers more stability with its dominant HIV franchise contributing significantly to revenue, supported by strong market share and new long-acting injectable programs like Yeztugo, though it faces its own headwinds from Medicare redesigns. Both companies hold dominant positions in their core markets with a global presence and a track record of delivering shareholder returns, making the decision between them a matter of weighing Bristol Myers' high-growth, high-leverage strategy against Gilead's more established, diversified revenue streams in HIV and liver disease.